Shu Wang

Shu Wang is an accomplished researcher with extensive experience in the biotechnology and pharmaceutical fields, currently serving as a Principal Investigator and Senior Research Investigator at Incyte since August 2020. Wang's expertise includes developing cell lines for monoclonal and bispecific antibodies, creating antigen binding assays, and managing project timelines for outsourced work. Prior positions include Senior Scientist roles at WuXi Advanced Therapies and Klus Pharma, where the focus was on developing producer cell lines for viral applications and therapeutic antibodies. Previous experience also encompasses significant contributions at Bristol-Myers Squibb, JFK Medical Center, Princeton University, the University of Pennsylvania, and Yale University School of Medicine. Shu Wang holds a Ph.D. in Human Molecular Genetics and a Master’s in Biochemistry from Fudan University, complemented by a Bachelor’s in Biology from Suzhou University of Science and Technology.